Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or …

Abstract:

e11058 Background: The PI3K/Akt/mTOR pathway, a key regulator of cellular proliferation, cellular metabolism, and angiogenesis, is constitutively activated in aromatase inhibitor–resistant breast cancer. Everolimus (EVE), an inhibitor of the PI3K/Akt/mTOR pathway, has single-agent activity and provides additional efficacy to long-term estrogen deprivation when combined with letrozole in the neoadjuvant setting. Combination of EVE and exemestane may improve outcomes for patients ER+ breast cancer refractory to nonsteroidal aromatase inhibitors (NSAI). Methods: In this multinational, double-blind, placebo-controlled phase III study, postmenopausal women ≥18 years old with ER+ locally advanced or metastatic breast cancer whose disease was refractory to NSAI and documented recurrence or progression were stratified by sensitivity to prior hormonal therapy and the presence of visceral …

Año de publicación:

2011

Keywords:

Fuente:

google